Sarepta Therapeutics (SRPT) Stock Forecast & Price Prediction

Estimation of the future price movement of Sarepta Therapeutics stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target

Current $127.90

Concensus $148.67

Low $94.00

Median $158.00

High $187.00

Based on analysts projections #SRPT is expected to experience a positive growth trajectory over the next year.

The current average SRPT price target, as estimated by these analysts, is $148.67.

The predictions for the future SRPT stock price range from a low of $94.00 to a high of $187.00, highlighting the variability of market expectations for SRPT.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

SRPT stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Matthew Harrison
Morgan Stanley
March 1, 2023 Buy 187.00 145.01
Credit Suisse January 10, 2023 Sell 114.00 117.53
Needham January 10, 2023 Buy 160.00 117.53
BTIG December 22, 2022 Buy 160.00 132.13
UBS December 16, 2022 Buy 158.00 123.56
Gil Blum
November 3, 2022 Buy 158.00 105.01
Morgan Stanley September 8, 2022 Buy 135.00 116.57
Hartaj Singh
August 15, 2022 Buy 150.00 109.00
Morgan Stanley August 3, 2022 Sell 100.00 95.20
Needham July 29, 2022 Buy 162.00 93.96
Morgan Stanley July 15, 2022 Sell 80.00 84.04
Goldman Sachs May 24, 2022 Buy 155.00 68.84
Zhiqiang Shu
Berenberg Bank
March 2, 2022 Sell 94.00 79.56
Gil Blum
March 2, 2022 Buy 150.00 79.56
Uy Ear
Mizuho Securities
January 10, 2022 Buy 160.00 76.15
Yun Zhong
January 5, 2022 Sell 125.00 84.09
Hartaj Singh
January 4, 2022 Sell 125.00 89.16
Judah Frommer
Credit Suisse
October 15, 2021 Sell 95.00 84.19

Sarepta Therapeutics (SRPT) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if Sarepta Therapeutics is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.

Strong Buy

Financial Scores

Updated on: 29/02/2024

Altman Z-Score: 2.2

Piotroski Score: 5.0

ESG Score

Updated on: 29/02/2024

Environmental: 64.4

Social: 65.7

Governance: 65.2

Financial Health

Updated on: 29/02/2024

DCF: Buy

ROE: Buy

ROA: Strong Buy

Debt to equity ratio: Strong Buy

Price to earnings ratio: Strong Buy

Price to book ratio: Neutral

SRPT Discounted Cash Flow

Updated on: 29/02/2024

Discounted Cash Flow Value

Current Price

SRPT Revenues by Segment

Updated on: 29/02/2024

No available data

Revenue from Contract with Customer, Excluding Assessed Tax

SRPT Revenues by Region

Updated on: 29/02/2024

Rest of World

SRPT Notes Due

Updated on: 29/02/2024


There are no data to display

Sarepta Therapeutics (SRPT) Social Sentiments

Monitoring bullish and bearish sentiments towards Sarepta Therapeutics on Twitter and Stocktwits could help to forecast an upward or downward trend in Sarepta Therapeutics stock price.

No social results for SRPT

Analyzing the Stock Forecast for Sarepta Therapeutics: Betting on Biotech's Future Success

Sarepta Therapeutics: A Biotech Bet on the Future Sarepta Therapeutics Inc. (SRPT) is a biotechnology company that specializes in gene therapies and RNA-targeted treatments for rare genetic diseases. Founded in 1980, Sarepta has been at the forefront of precision medicine, striving to provide innovative therapies for disorders with no cure. The company's flagship drug is eteplirsen, a treatment for Duchenne... Read more

Maximizing Returns: Using Stock Prediction to Invest in the Booming Biotech Industry - A Closer Look at Sarepta Therapeutics

The Biotechnology sector of the stock market has been a hotbed of innovation and investment for several years. With cutting-edge treatments being developed for a variety of diseases, investors are taking notice of the potential profits that can be made by investing in this exciting field. One company that has long been on the radar of biotech investors is Sarepta... Read more